Clinical Trials & Results

Search or filter the listing below to find a trial or results of a completed trial.

View Actively Recruiting Clinical Trials

Click here to see trials currently recruiting participants

Filter

Health Condition

Toggle

Study Status

Toggle

Age group

Toggle

Gender

Toggle

Phase

Toggle

Study Types

Toggle

Showing 20 of 238 Results

No results found

Please change the filter settings to find the product(s) you are looking for. You can also use the search function to look up a product.

Clear Filters

A Pharmacokinetic and Safety study comparing Fluticasone Propionate and Albuterol Sulfate to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old

respiratory-icon.png
Condition(s):
Respiratory
Status:
Recruiting
Requirements:
4 Years to 11 Years
Interventions:
Drug: TEV-56248
Learn more The primary objectives of this study are to determine the pharmacokinetic (PK) profile of fluticasone propionate (Fp) and albuterol sulfate (ABS), delivered in combination, from a single dose of TEV-56248 in participants with asthma, to compare the PK profiles of Fp for different dose strengths of TEV-56248 to that of fluticasone propionate multidose dry powder inhaler (Fp MDPI), and to compare the PK profiles of ABS between the 2 different strengths of TEV-56248.

A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod

brain-icon.png
Condition(s):
Relapsing Remitting Multiple Sclerosis
Status:
Completed
Requirements:
18 Years to 50 Years
Interventions:
Drug: laquinimod 0.3 | Drug: laquinimod 0.6 | Other: Placebo
Learn more Please refer to ClinicalTrials.gov for a description of the trial

A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy Safety and Efficacy Study (TOPAS-MSA)

brain-icon.png
Condition(s):
Multiple System Atrophy
Status:
Recruiting
Requirements:
30 Years and older
Interventions:
Drug: TEV-56286 (emrusolmin, anle138b)
Learn more The primary objective of the study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the study is to evaluate specific efficacy parameters of TEV-56286. Another secondary objective is to evaluate the safety and tolerability of TEV-56286. The planned study period per participant is 56 weeks including a screening period (up to 4 weeks), a 48-week double-blind treatment period, and a follow-up visit (approximately 4 weeks after the end of the double-blind treatment period). The study duration will be approximately 27 months.

A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo

allergy-icon.png
Condition(s):
Vitiligo
Status:
Recruiting
Requirements:
18 Years to 75 Years
Interventions:
Drug: TEV-53408
Learn more The primary objective of the trial is to evaluate the safety of TEV-53408 administered subcutaneously for the treatment of adults with vitiligo. Another primary objective is to evaluate the efficacy of TEV-53408. A secondary objective is to further evaluate the safety of TEV-53408. The planned study period per participant is 84 weeks including a screening period (up to 4 weeks), a 24-week open-label treatment period, a 16-week washout period, and a 40-week follow-up period.

Absolute Bioavailability of Reslizumab in Healthy Subjects

disease-icon.png
Condition(s):
Absolute Bioavailability
Status:
Completed
Requirements:
18 Years to 45 Years
Interventions:
Drug: Reslizumab IV | Drug: Reslizumab SC
Learn more Please refer to ClinicalTrials.gov for a description of the trial

Adenovirus Vaccine Pregnancy Registry

inflammation-icon.png
Condition(s):
Adenovirus
Status:
Withdrawn
Requirements:
17 Years to 50 Years
Learn more Please refer to ClinicalTrials.gov for a description of the trial

Albuterol HFA MDI in Pediatric Participants With Asthma

respiratory-icon.png
Condition(s):
Asthma
Status:
Completed
Requirements:
4 Years to 11 Years
Interventions:
Drug: Albuterol | Drug: Placebo | Drug: Proventilֲ® HFA
Learn more Please refer to ClinicalTrials.gov for a description of the trial

An Efficacy and Safety Profile of Inhaled TV48108 in Healthy Volunteers and COPD Patients

respiratory-icon.png
Condition(s):
Chronic Obstructive Pulmonary Disease
Status:
Terminated
Requirements:
20 Years to 75 Years
Interventions:
Drug: TV48108 | Drug: Placebo
Learn more Please refer to ClinicalTrials.gov for a description of the trial

An Efficacy and Safety Study of Fremanezumab in Adults With Migraine

headache-icon.png
Condition(s):
Migraine Prophylaxis
Status:
Completed
Requirements:
18 Years to 70 Years
Interventions:
Drug: Fremanezumab | Drug: Placebo
Learn more Please refer to ClinicalTrials.gov for a description of the trial

Assess Safety and PK of ADASUVE® in Children and Adolescents Using an Antipsychotic Medication

psychiatry-icon.png
Condition(s):
BiPolar
Status:
Completed
Requirements:
10 Years to 17 Years
Interventions:
Drug: ADASUVEֲ®
Learn more Please refer to ClinicalTrials.gov for a description of the trial

Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older

allergy-icon.png
Condition(s):
Seasonal Female, Maleergic Rhinitis | Hayfever
Status:
Completed
Requirements:
12 Years and older
Interventions:
Drug: Beclomethasone dipropionate HFA Nasal Aerosol | Drug: Placebo
Learn more Please refer to ClinicalTrials.gov for a description of the trial

Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate Compared to Placebo

brain-icon.png
Condition(s):
Relapsing Remitting Multiple Sclerosis
Status:
Completed
Requirements:
18 Years to 55 Years
Interventions:
Drug: Glatiramer acetate (GA) | Drug: Placebo
Learn more Please refer to ClinicalTrials.gov for a description of the trial

Assess Tolerability, Safety and Pharmacology of hGH-ViaDerm™ System in Adults With GH-Deficiency

muscle-icon.png
Condition(s):
Growth Hormone Deficiency
Status:
Completed
Requirements:
20 Years to 60 Years
Interventions:
Drug: hGH-ViaDermג„¢ System (hGH or somatropin) | Device: hGH-ViaDermג„¢ System
Learn more Please refer to ClinicalTrials.gov for a description of the trial

Assessment of LBR-101 In Chronic Migraine

headache-icon.png
Condition(s):
Chronic Migraine
Status:
Completed
Requirements:
18 Years to 65 Years
Interventions:
Biological: LBR-101 High Dose | Biological: LBR-101 Low Dose | Biological: Placebo
Learn more Please refer to ClinicalTrials.gov for a description of the trial

Azilect + Antidepressant Chart Review

psychiatry-icon.png
Condition(s):
Serotonin Syndrome
Status:
Completed
Requirements:
Child, Adult, Older Adult
Interventions:
Drug: Group R+AD Rasagiline + Antidepressant | Drug: Group R Rasagiline | Drug: Group AD Anti-PD + Antidepressant
Learn more Please refer to ClinicalTrials.gov for a description of the trial

Azilect® In Wearing-Off 

brain-icon.png
Condition(s):
Parkinson's Disease
Status:
Completed
Requirements:
18 Years and older
Interventions:
Drug: Azilectֲ®
Learn more Please refer to ClinicalTrials.gov for a description of the trial

Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel 

cancer-icon.png
Condition(s):
Chemotherapy-induced Neutropenia
Status:
Completed
Requirements:
18 Years and older
Interventions:
Biological: Neugranin | Drug: Pegfilgrastim | Drug: Chemotherapy
Learn more Please refer to ClinicalTrials.gov for a description of the trial

Beclomethasone Dipropionate in Participants At Least 12 Years Old With Persistent Asthma

respiratory-icon.png
Condition(s):
Asthma
Status:
Completed
Requirements:
12 Years and older
Interventions:
Drug: Beclomethasone dipropionate | Drug: Placebo | Drug: Albuterol/salbutamol
Learn more Please refer to ClinicalTrials.gov for a description of the trial

Bendamustine Hydrochloride and Rituximab Compared With R-CVP or R-CHOP in Patients With Lymphoma

cancer-icon.png
Condition(s):
Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma
Status:
Completed
Requirements:
18 Years and older
Interventions:
Drug: bendamustine | Drug: rituximab | Drug: vincristine | Drug: prednisone | Drug: cyclophosphamide | Drug: doxorubicin
Learn more Please refer to ClinicalTrials.gov for a description of the trial

Bendamustine Hydrochloride for the Treatment of Relapsed or Refractory Acute Leukemia

cancer-icon.png
Condition(s):
Leukemia
Status:
Completed
Requirements:
1 Year to 20 Years
Interventions:
Drug: Bendamustine
Learn more Please refer to ClinicalTrials.gov for a description of the trial